Sino Biopharmaceutical Limited specialises in the development, manufacture and marketing of biopharmaceutical products primarily for the treatment of cancer, ophthalmia, hepatitis, orthopedic diseases and respiratory disorders. Net sales break down by category of products as follows: - chemical medicine products and biopharmaceutical drugs (97.6%); - other (2.4%).

Employees

24,437

Sector

Pharmaceuticals

Calendar

2025-03-27 - Q4 2024 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
24-12-10	3.330 $	0.00%	73,785,712
24-12-09	3.330 $	+1.52%	79,080,520
24-12-06	3.280 $	+1.23%	56,007,240
24-12-05	3.240 $	-2.41%	47,312,810
24-12-04	3.320 $	-0.90%	30,341,220

Delayed Quote Hong Kong S.E., December 10, 2024 at 03:08 am EST

More quotes

Income Statement and Estimates

income-statement-evolution-chart SINO-BIOPHARMACEUTICAL-LI

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.111CNY

Average target price

4.153CNY

Spread / Average Target

+33.47%

Consensus

Profit revisions

estimates-change-chart SINO-BIOPHARMACEUTICAL-LI

Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart SINO-BIOPHARMACEUTICAL-LI

Company calendar

Market Closed - Hong Kong S.E. Other stock markets 03:08:32 2024-12-10 am EST			5-day change	1st Jan Change
3.330 ^HKD	0.00%		+1.22%	-4.03%

Dec. 05	Sino Biopharmaceutical Enters Global Collaboration Contract for Asthma Drug	MT
Nov. 27	Sino Biopharmaceutical Gets Chinese Regulator's Marketing Approval for Endometrial Cancer Drug	MT

Capitalization	56.64B 60.62B 7.8B 7.37B 6.84B 6.1B 11.01B 662B 12.07B 85.01B 31.38B 272B 29.29B 28.65B 1,178B	P/E ratio 2024 *	17.5x	P/E ratio 2025 *	18.6x
Enterprise value	53.6B 57.36B 7.38B 6.97B 6.47B 5.77B 10.42B 626B 11.42B 80.43B 29.69B 257B 27.71B 27.1B 1,114B	EV / Sales 2024 *	1.82x	EV / Sales 2025 *	1.51x
Free-Float	-	Yield 2024 *	2.07%	Yield 2025 *	2.37%

Sino Biopharmaceutical Enters Global Collaboration Contract for Asthma Drug	Dec. 05	MT
Sino Biopharmaceutical Gets Chinese Regulator's Marketing Approval for Endometrial Cancer Drug	Nov. 27	MT
Sino Biopharmaceutical Limited Announces Approval for Marketing of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsule for the Indication of Treatment for Endometrial Cancer	Nov. 27	CI
Sino Biopharmaceutical Submits New Indication Application for Liver Cancer Drug Combo	Nov. 21	MT
Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsule in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Carcinoma	Nov. 20	CI
Sino Biopharm Injects 142 Million Yuan into LaNova Medicines	Nov. 20	MT
Lixin Pharmaceutical Technology Co., Ltd announced that it has received CNY 142 million in funding from Sino Biopharmaceutical Limited	Nov. 19	CI
Sino Biopharmaceutical's Fourth-Gen EGFR Inhibitor's IND Application Gets US FDA Nod	Nov. 15	MT
Sino Biopharmaceutical Limited Announces Approval for Clinical Trials of the Fourth-Generation EGFR Inhibitor "TQB3002" in the United States	Nov. 14	CI
Sino Biopharmaceutical Cancer Drug Gets Marketing Approval in China	Nov. 10	MT
Sino Biopharmaceutical Limited Obtains Approval for Marketing of KRAS G12C Inhibitor "Garsorasib"	Nov. 10	CI
Sino Biopharmaceutical's Cancer Drug Gets Marketing Nod from NMPA After Phase III Trials	Oct. 21	MT
Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsules in Combination with Chemotherapy for First-Line Treatment of Advanced Soft Tissue Sarcoma	Oct. 21	CI

Nomura Adjusts Sino Biopharmaceutical's Price Target to HK$6.42 From HK$6.16, Keeps at Buy	Aug. 14	MT
Nomura Adjusts Sino Biopharmaceutical’s Price Target to HK$6.16 From HK$6.63, Keeps at Buy	Mar. 15	MT
Nomura Adjusts Sino Biopharmaceutical's Price Target to HK$6.63 From HK$7.43, Keeps at Buy	23-08-02	MT
Nomura Adjusts Sinobiopharma's Price Target to HK$7.43 From HK$7.78, Keeps at Buy	23-03-10	MT
UBS Adjusts Sino Biopharmaceutical's Price Target to HK$7.5 From HK$8, Keeps at Buy	22-08-25	MT

Sino Biopharmaceutical Limited Stock

Equities

1177

KYG8167W1380

Pharmaceuticals

Valuation: Sino Biopharmaceutical Limited

Chart: Sino Biopharmaceutical Limited

Latest news: Sino Biopharmaceutical Limited

Analysts' recommendations: Sino Biopharmaceutical Limited

Press Releases: Sino Biopharmaceutical Limited

News in other languages: Sino Biopharmaceutical Limited

Quotes and Performance

Course Extremes

Managers and Directors: Sino Biopharmaceutical Limited

ETFs: Sino Biopharmaceutical Limited

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

Sino Biopharmaceutical (1177.HK) Announces 2024 Interim Results	Aug. 13	AQ
Sino Biopharmaceutical : 2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT	Apr. 29	PU
Sino Biopharm (1177.HK) Announces 2023 Annual Results	Mar. 29	AQ
Sino Biopharmaceutical (1177.HK) Announces 2023 Interim Results	23-08-25	AQ
Sino Biopharmaceutical : 2022 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT	23-06-08	PU

Borse Cina : chiudono miste, in rialzo Hong Kong con decisione su tassi	Apr. 22
Las acciones de Hong Kong terminan planas tras una sesión volátil -- Market Talk	23-08-07
MÄRKTE ASIEN/Fester - Hoffen auf Zinspause	23-04-14
MÄRKTE ASIEN/Überwiegend aufwärts - Singapurer Zentralbank hält still	23-04-14
La actualización de la Lista Nacional de Medicamentos Reembolsables de China cumple las expectativas -- Market Talk	23-01-19

1 week	+1.22%
Current month	+2.46%
1 month	-3.48%
3 months	+6.05%
6 months	+16.84%
Current year	-4.03%

Director	Title	Age	Since
S Y Tse CEO	Chief Executive Officer	28	2022-07-27
Chun Ling Li DFI	Director of Finance/CFO	53	1995-12-31
Hsin Tse IRC	Investor Relations Contact	54	2013-04-24

Manager	Title	Age	Since
Ping Tse CHM	Chairman	72	2000-02-01
Cheung Ling Cheng BRD	Director/Board Member	60	2017-04-09
Hsin Tse BRD	Director/Board Member	54	1995-07-31

Name	Weight	AuM	1st Jan change	Investor Rating
KRANESHARES MSCI ALL CHINA HEALTH CARE INDEX UCITS ETF - USD	2.40%	1 M€	-20.08%	-
LONCAR CHINA BIOPHARMA ETF - DISTRIBUTING - USD	2.02%	4 M€	-27.92%
KRANESHARES MSCI CHINA ESG LEADERS UCITS ETF ACC - USD	0.82%	2 M€	-2.90%	-

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
SINO BIOPHARMACEUTICAL LIMITED	0.00%	+1.22%	-1.19%	-42.29%	7.8B
ELI LILLY AND COMPANY	-0.35%	-1.38%	+37.34%	+228.55%	724B
NOVO NORDISK A/S	+0.03%	+0.03%	+16.93%	+108.39%	491B
JOHNSON & JOHNSON	-0.37%	-1.91%	-3.62%	-9.70%	360B
ABBVIE INC.	-0.42%	-3.08%	+16.31%	+40.20%	312B
MERCK & CO., INC.	-2.09%	-0.27%	-2.67%	+39.88%	263B
ROCHE HOLDING AG	-1.44%	+0.08%	+0.16%	-32.44%	236B
ASTRAZENECA PLC	-1.53%	-2.21%	+4.52%	+28.79%	212B
NOVARTIS AG	-0.70%	-4.41%	+3.90%	+19.10%	204B
AMGEN INC.	-0.46%	-0.70%	+1.55%	+31.05%	149B
Average	-0.71%	-0.64%	+7.32%	+41.15%	295.8B
Weighted average by Cap.	-0.63%	-0.50%	+13.67%	+82.76%

	2024 *	2025 *
Net sales	29.47B 31.54B 4.06B 3.84B 3.56B 3.17B 5.73B 344B 6.28B 44.23B 16.33B 141B 15.24B 14.91B 613B	32.55B 34.84B 4.48B 4.24B 3.93B 3.5B 6.33B 380B 6.93B 48.85B 18.04B 156B 16.83B 16.46B 677B
Net income	3.5B 3.75B 482M 456M 423M 377M 681M 40.89B 746M 5.25B 1.94B 16.78B 1.81B 1.77B 72.79B	3.21B 3.44B 442M 418M 388M 346M 624M 37.51B 684M 4.82B 1.78B 15.39B 1.66B 1.62B 66.76B
Net Debt	-3.05B -3.26B -420M -397M -368M -328M -593M -35.62B -649M -4.58B -1.69B -14.62B -1.58B -1.54B -63.4B	-7.65B -8.19B -1.05B -996M -924M -824M -1.49B -89.39B -1.63B -11.48B -4.24B -36.68B -3.96B -3.87B -159B